Update on the COVID-19 pandemic

Information regarding COVID-19 is in constant change, as is the situation regarding vaccination and prioritization for immune-compromised individuals.

If you have any COVID-19-related questions, we’ve created a specific COVID section on our website that can be accessed by clicking here or by selecting the “News & Events” tab from our homepage. In this section, you’ll find the latest news and information about the pandemic in Canada from trustworthy and reliable sources.

Any specific questions that you may have regarding the COVID-19 vaccination, delays between vaccine dosing, and prioritization within your province are best answered by your healthcare team. They’re the ones who know you and your particular situation and are therefore in a position to best address your unique concerns.

Created by, and entirely focused on, Canadians impacted by myeloma, Myeloma Canada is the only national charitable organization committed to providing you with the most up-to-date and reliable information on myeloma. Some of the ways we do this is through our monthly e-newsletter, “Myeloma Matters”, as well as through our social media platforms.

Please don’t hesitate to contact us at contact@myeloma.ca or toll-free at 1-888-798-5771 with any questions regarding our programs and services.


Make a donation

Myeloma Canada Research Network

Redefining and Revolutionizing Research

The mission of the Myeloma Canada Research Network is to:

  • Conduct innovative Phase I and II clinical and translational research in a collaborative manner to improve patient outcomes in multiple myeloma
  • Publish evidence-based and peer reviewed consensus statements on the diagnosis and treatment of myeloma
  • Develop a nationwide myeloma patient database

As a patient organization, Myeloma Canada promotes its commitment to patient-focused clinical research in collaboration with the Myeloma Canada Research Network (MCRN). The unique network of Canadian world-class myeloma researchers brings Canadian-designed clinical trials to patients, while promoting the sharing of scientific data and expertise amongst its members, to gain access to new therapies in an accelerated manner for Canadian patients, leading to improved overall outcomes.